Historical record - last NADAC effective date: 1/4/2017
Product Information
EXFORGE HCT 10-160-12.5 MG TAB is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $8.4532 per EA under NDC 00078056115. Its NADAC has been published 191 times since Nov 28, 2013.
FDA first approved this application on Apr 30, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10; 12.5; 160 mg/1; mg/1; mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078056115
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
1/4/2017
Active Ingredients
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTANApproval Type
New Drug (NDA)
FDA Application
NDA022314FDA Approved
4/30/2009
TE Code
AB
On Market Since
4/4/2009
Pharmacological Classes
Price Statistics
The NADAC for EXFORGE HCT 10-160-12.5 MG TAB has been published 191 times since Nov 28, 2013, and over the history we have for it it has risen 74.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.4532 per EA |
|---|---|
| All-time high | $8.4532 (Jul 19, 2017) |
| All-time low | $4.8365 (Nov 28, 2013) |
| Median price | $6.6658 |
| Average price | $6.7226 |
| Largest weekly change | +19.5% (Apr 15, 2015) |
| Weeks tracked | 191 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+74.8%
Last surveyed Jul 19, 2017 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the amlodipine valsartan and hydrochlorothiazide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of EXFORGE HCT 10-160-12.5 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for EXFORGE HCT 10-160-12.5 MG TAB, manufactured by Novartis Pharmaceuticals Corporation, is $8.4532 per EA (NDC 00078056115), effective Jul 19, 2017.
How has the price of EXFORGE HCT 10-160-12.5 MG TAB changed over time?
Over the history we have for it, the NADAC for EXFORGE HCT 10-160-12.5 MG TAB has risen 74.8%. It has been tracked across 191 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for EXFORGE HCT 10-160-12.5 MG TAB?
Since Nov 28, 2013, the NADAC for EXFORGE HCT 10-160-12.5 MG TAB has ranged from a low of $4.8365 (Nov 28, 2013) to a high of $8.4532 (Jul 19, 2017), with a median of $6.6658 per EA.
Are there cheaper alternatives to EXFORGE HCT 10-160-12.5 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of EXFORGE HCT 10-160-12.5 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures EXFORGE HCT 10-160-12.5 MG TAB?
EXFORGE HCT 10-160-12.5 MG TAB (NDC 00078056115) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.